

Table S1 Baseline characteristics of TNBC and HER2⁺/HoR⁻ patients with T1 tumors

Characteristics	TNBC (N=6,953)	HER2 ⁺ /HoR ⁻ (N=2,648)	P value
Median follow-up (months) [IQR]	22 [10–34]	22 [10–35]	0.851
Age (mean ± SD)	57.8±11.7	56.7±11.1	<0.001*
Race, n (%)			<0.001*
White	5,202 (75.3)	1,934 (73.4)	
Black	1,242 (18.0)	333 (12.7)	
Others ^a	467 (6.7)	367 (13.9)	
Marital status, n (%)			0.006*
Married	4,173 (63.6)	1,669 (66.7)	
Not married ^b	2,391 (36.4)	834 (33.3)	
Laterality, n (%)			0.333
Left	3,531 (50.8)	1,374 (51.9)	
Right	3,422 (49.2)	1,274 (48.1)	
Grade, n (%)			<0.001*
I	163 (2.4)	42 (1.6)	
II	1,435 (21.1)	705 (27.7)	
III/IV	5,204 (76.5)	1,802 (70.7)	
AJCC stage, n (%)			<0.001*
I	5,857 (84.2)	2,071 (78.2)	
II	842 (12.1)	427 (16.1)	
III	254 (3.7)	150 (5.7)	
N stage, n (%)			<0.001*
N0	5,642 (81.1)	1,963 (74.1)	
N1	1,057 (15.2)	535 (20.2)	
N2	175 (2.5)	98 (3.7)	
N3	79 (1.2)	52 (2.0)	
Radiation, n (%)			<0.001*
Yes	3,610 (54.3)	1,099 (43.5)	
No	3,037 (45.7)	1,427 (56.5)	

*, indicates statistical significance; ^a, other includes American Indian/Alaskan native, and Asian/Pacific Islander; ^b, not married includes divorced, separated, single (never married), unmarried or domestic partner and widowed. TNBC, triple negative breast cancer; HER2⁺/HoR⁻, human epidermal growth factor receptor-2 positive/hormone receptor negative; IQR, interquartile range; SD, standard deviation; AJCC, American Joint Committee on Cancer.